AP643A - Substituted benzylaminopiperidine compounds. - Google Patents

Substituted benzylaminopiperidine compounds. Download PDF

Info

Publication number
AP643A
AP643A APAP/P/1996/000850A AP9600850A AP643A AP 643 A AP643 A AP 643A AP 9600850 A AP9600850 A AP 9600850A AP 643 A AP643 A AP 643A
Authority
AP
ARIPO
Prior art keywords
compound
salts
trifluoromethyl
amino
methoxy
Prior art date
Application number
APAP/P/1996/000850A
Other languages
English (en)
Other versions
AP9600850A0 (en
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600850A0 publication Critical patent/AP9600850A0/xx
Application granted granted Critical
Publication of AP643A publication Critical patent/AP643A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/1996/000850A 1995-08-24 1996-08-24 Substituted benzylaminopiperidine compounds. AP643A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24

Publications (2)

Publication Number Publication Date
AP9600850A0 AP9600850A0 (en) 1996-10-31
AP643A true AP643A (en) 1998-04-24

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000850A AP643A (en) 1995-08-24 1996-08-24 Substituted benzylaminopiperidine compounds.

Country Status (41)

Country Link
US (1) US6506775B1 (de)
EP (2) EP1114817B1 (de)
JP (1) JP3084069B2 (de)
KR (1) KR100288673B1 (de)
CN (1) CN1153764C (de)
AP (1) AP643A (de)
AR (1) AR006305A1 (de)
AT (2) ATE258166T1 (de)
AU (1) AU702698B2 (de)
BG (1) BG64126B1 (de)
BR (1) BR9609989A (de)
CA (1) CA2227814C (de)
CO (1) CO4480738A1 (de)
CZ (1) CZ297543B6 (de)
DE (2) DE69631390T2 (de)
DK (2) DK0861235T3 (de)
DZ (1) DZ2086A1 (de)
ES (2) ES2163017T3 (de)
HR (1) HRP960386B1 (de)
HU (1) HU225480B1 (de)
IL (1) IL119078A (de)
IS (1) IS1947B (de)
MA (1) MA23961A1 (de)
MX (1) MX9801467A (de)
MY (1) MY114800A (de)
NO (1) NO310720B1 (de)
NZ (1) NZ308207A (de)
OA (1) OA10666A (de)
PE (2) PE1398A1 (de)
PL (1) PL186773B1 (de)
PT (2) PT1114817E (de)
RO (1) RO119299B1 (de)
RU (1) RU2152930C2 (de)
SI (2) SI0861235T1 (de)
SK (1) SK282925B6 (de)
TN (1) TNSN96107A1 (de)
TR (1) TR199800300T1 (de)
TW (1) TW340842B (de)
UA (1) UA48981C2 (de)
WO (1) WO1997008144A1 (de)
YU (1) YU49122B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
ES2211520T3 (es) * 1999-05-06 2004-07-16 Pfizer Products Inc. Compuestos de benzolactama sustituidos.
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
ES2190781T3 (es) * 1999-05-21 2003-08-16 Pfizer Prod Inc Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil-aminometilcromano.
ES2211455T3 (es) * 1999-10-18 2004-07-16 Pfizer Products Inc. Procedimiento para la preparacion de compuestos eteres ciclicos piperidinilaminometil trifluorometilicos.
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ, インコーポレイテッド 4−フェニル置換テトラヒドロイソキノリンおよびその使用方法
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
AU2004232799A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
CA2566920A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of (+)-(2s, 3s)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine
US20060063766A1 (en) 2004-07-15 2006-03-23 Molino Bruce F Use of aryl- and heteroaryl-substituted tetrahydroisoquinolines to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP3536690A1 (de) 2007-01-10 2019-09-11 MSD Italia S.r.l. Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
EP2170076B1 (de) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ, インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP4079856A1 (de) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
EP3453762B1 (de) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Sina-zusammensetzungen
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2925888B1 (de) 2012-11-28 2017-10-25 Merck Sharp & Dohme Corp. Zusammensetzungen und verfahren zur behandlung von krebs
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (de) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5-inhibitoren
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000331A1 (en) * 1991-06-20 1993-01-07 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
WO1993001170A1 (en) * 1991-07-01 1993-01-21 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
PL169993B1 (pl) * 1991-03-26 1996-09-30 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL PL
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
CA2216701A1 (en) 1995-03-27 1996-10-03 Akira Okayama Piperidine derivatives
DK0780375T3 (da) * 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000331A1 (en) * 1991-06-20 1993-01-07 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
WO1993001170A1 (en) * 1991-07-01 1993-01-21 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles

Also Published As

Publication number Publication date
SI1114817T1 (en) 2004-06-30
HUP9901159A2 (hu) 1999-07-28
NO310720B1 (no) 2001-08-20
TW340842B (en) 1998-09-21
BR9609989A (pt) 1999-07-06
PL186773B1 (pl) 2004-02-27
PL325332A1 (en) 1998-07-20
DE69631390D1 (de) 2004-02-26
HU225480B1 (en) 2006-12-28
DE69616817T2 (de) 2002-04-04
WO1997008144A1 (en) 1997-03-06
JPH10510554A (ja) 1998-10-13
MA23961A1 (fr) 1997-04-01
EP1114817A1 (de) 2001-07-11
AP9600850A0 (en) 1996-10-31
HK1014935A1 (en) 1999-10-08
YU47896A (sh) 1998-12-23
KR100288673B1 (ko) 2001-05-02
ATE208377T1 (de) 2001-11-15
AU702698B2 (en) 1999-03-04
BG64126B1 (bg) 2004-01-30
CO4480738A1 (es) 1997-07-09
CZ297543B6 (cs) 2007-02-07
NZ308207A (en) 1998-07-28
AU5776996A (en) 1997-03-19
IL119078A0 (en) 1996-11-14
PT1114817E (pt) 2004-05-31
EP0861235B1 (de) 2001-11-07
CA2227814C (en) 2002-12-31
IL119078A (en) 2003-11-23
NO980751L (no) 1998-02-23
EP1114817B1 (de) 2004-01-21
PT861235E (pt) 2002-03-28
SK20798A3 (en) 1999-03-12
YU49122B (sh) 2004-03-12
MX9801467A (es) 1998-05-31
NO980751D0 (no) 1998-02-23
CN1193961A (zh) 1998-09-23
DE69631390T2 (de) 2004-11-25
TNSN96107A1 (fr) 2005-03-15
RU2152930C2 (ru) 2000-07-20
DK1114817T3 (da) 2004-04-26
SK282925B6 (sk) 2003-01-09
JP3084069B2 (ja) 2000-09-04
IS4644A (is) 1997-12-30
TR199800300T1 (xx) 1998-06-22
UA48981C2 (uk) 2002-09-16
PE1398A1 (es) 1998-02-27
CA2227814A1 (en) 1997-03-06
OA10666A (en) 2002-11-25
PE20010700A1 (es) 2001-07-09
US6506775B1 (en) 2003-01-14
DE69616817D1 (de) 2001-12-13
KR19990044077A (ko) 1999-06-25
SI0861235T1 (en) 2002-04-30
ATE258166T1 (de) 2004-02-15
HRP960386B1 (en) 2002-04-30
ES2163017T3 (es) 2002-01-16
DZ2086A1 (fr) 2002-07-22
DK0861235T3 (da) 2001-12-27
EP0861235A1 (de) 1998-09-02
MY114800A (en) 2003-01-31
BG102288A (en) 1998-09-30
HRP960386A2 (en) 1998-04-30
HUP9901159A3 (en) 2000-05-29
CZ52198A3 (cs) 1999-01-13
RO119299B1 (ro) 2004-07-30
IS1947B (is) 2004-10-13
CN1153764C (zh) 2004-06-16
ES2211684T3 (es) 2004-07-16
AR006305A1 (es) 1999-08-25

Similar Documents

Publication Publication Date Title
AP643A (en) Substituted benzylaminopiperidine compounds.
US5744480A (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP0699199B1 (de) Benzylaminochinuclidinen mit ein durch ein heteronom substituiertes alkyl als substanz p antagoniste
JP2500279B2 (ja) アザ二環式化合物、これを含有する医薬組成物及び治療のための使用方法
JPH0757748B2 (ja) 3−アミノピペリジン誘導体及び関連する窒素含有複素環化合物
US5332817A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles
CA2193468C (en) 3-[(5-substituted benzyl)amino]-2-phenylpiperidines as substance p antagonists
US6329396B1 (en) Substituted benzylaminopiperidine compounds
US4705807A (en) Amine derivatives
JP3172461B2 (ja) サブスタンスpアンタゴニストとしての3−[(5−置換ベンジル)アミノ]−2−フェニルピペリジン
JP2822274B2 (ja) P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US20050256162A1 (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
HK1000247B (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles